Published cost-effectiveness analyses of GLP-1 receptor agonists for obesity and diabetes have shown mixed results, but their wide-ranging benefits may have been sold short.
Virtual Practice in Obesity Management Through Simulated Scenarios healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also express concern about cost and patient accessibility.
Targeted News Service provides Washington Bureau coverage, federal contract and contracting information for awards and for subcontracting opportunities, a congressional vote chart, federal and congressional press releases.